# Apmonia Therapeutics

> Developing anti-cancer immunotherapy

Business model and tags: B2B, Pharma & life sciences, Has in-house R&D

## About Apmonia Therapeutics

Biotechnology company specializing in developing anti-cancer immunotherapy targeting tumors with high levels of TSP-1 protein using proprietary peptide therapy and companion diagnostic kit

## Key facts

- **Industry**: Biotechnology
- **Company size**: 11–50 employees
- **Headquarters**: reims, grand est, France
- **Founded**: 2019
- **Revenue**: €4.6M – €36.5M (Tamtam estimate)
- **Website**: [apmonia-therapeutics.com](http://apmonia-therapeutics.com/)
- **LinkedIn**: [linkedin.com/company/apmonia-therapeutics](https://www.linkedin.com/company/apmonia-therapeutics)

## Apmonia Therapeutics at a glance

Apmonia Therapeutics is a B2B company in the Biotechnology industry, headquartered in reims, grand est, France.

Apmonia Therapeutics was founded in 2019.

Apmonia Therapeutics has 11–50 employees.

Apmonia Therapeutics's revenue is €4.6M – €36.5M (Tamtam estimate).

## Frequently asked questions about Apmonia Therapeutics

### What is Apmonia Therapeutics's revenue?

Tamtam estimates Apmonia Therapeutics's annual revenue at €4.6M – €36.5M.

### How many employees does Apmonia Therapeutics have?

Apmonia Therapeutics has 11–50 employees.

### Where is Apmonia Therapeutics headquartered?

Apmonia Therapeutics is headquartered in reims, grand est, France.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/apmonia-therapeutics